Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» povorcitinib
povorcitinib
Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose
Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose
Endpoints
AAD
Incyte
JAK inhibitors
povorcitinib
vitiligo
Flag link:
Incyte reports data from Phase IIb vitiligo therapy trial
Incyte reports data from Phase IIb vitiligo therapy trial
Clinical Trials Arena
Incyte
povorcitinib
vitiligo
clinical trials
Flag link:
Incyte reports new data from hidradenitis suppurativa therapy trial
Incyte reports new data from hidradenitis suppurativa therapy trial
Clinical Trials Arena
Incyte
clinical trials
hidradenitis suppurativa
povorcitinib
Flag link:
